PRESCRIBING FOR OLDER ADULTS AND PREGNANT WOMEN

Full Answer Section

         

• Risks:
  • Perinatal Complications: A small, but statistically significant, increased risk of certain neonatal complications, sometimes collectively referred to as "poor neonatal adaptation syndrome" (PNAS) or "neonatal abstinence syndrome" (NAS), including respiratory distress, jitteriness, irritability, feeding difficulties, and hypotonia. These are typically transient and resolve within days or weeks after birth.
  • Persistent Pulmonary Hypertension of the Newborn (PPHN): A very rare but serious condition. Some studies have shown a slightly increased risk with SSRI exposure in late pregnancy, though the absolute risk remains extremely low (e.g., 1-2 per 1000 live births compared to a baseline of 1 per 1000).
  • Cardiac Malformations: Early concerns about cardiac malformations (particularly septal defects) with SSRIs, especially paroxetine, have largely been mitigated for other SSRIs like sertraline, with most large studies showing no significant increased risk for overall major malformations. However, continuous monitoring and shared decision-making are crucial.
• Benefits:
  • Effective Treatment of MDD: For moderate to severe MDD, sertraline can significantly reduce depressive symptoms, improve maternal well-being, and reduce the risk of relapse during pregnancy and postpartum.
  • Reduced Risks of Untreated Depression: Untreated MDD in pregnancy is associated with significant risks including poor maternal self-care, inadequate prenatal care, increased rates of preterm birth, low birth weight, preeclampsia, poor maternal-infant bonding, and adverse neurodevelopmental outcomes for the child (Grigoriadis et al., 2013).
  • Relatively Low Fetal Risk Profile: Compared to other antidepressants and given the risks of untreated depression, sertraline has one of the best established safety profiles during pregnancy, with extensive research demonstrating its relative safety. It is also often preferred for breastfeeding due to very low levels in breast milk.

 

2. Non-FDA-Approved "Off-Label" Drug: Bupropion (Wellbutrin)

 

• Recommendation: Bupropion, an atypical antidepressant that inhibits the reuptake of norepinephrine and dopamine, is sometimes used off-label for MDD in pregnancy, particularly when there is a history of inadequate response to SSRIs or if comorbid conditions like ADHD or smoking cessation are present. Its use is considered off-label because while it's FDA-approved for MDD, its specific safety and efficacy for pregnant populations have not undergone dedicated, large-scale randomized controlled trials for this indication.
• Risks:
  • Cardiac Malformations: There have been historical concerns, particularly with a specific type of cardiac malformation called left ventricular outflow tract obstruction (LVOTO), reported in some early studies and a pregnancy registry. However, more recent and larger epidemiological studies have generally not confirmed an overall increased risk of major congenital malformations with first-trimester bupropion exposure, and the data remains somewhat inconsistent (DrOracle AI, 2025). The absolute risk, if any, is considered small and comparable to the general population's background risk for birth defects.
  • Spontaneous Abortion: Some studies have suggested a possible increased risk of miscarriage, though findings are not conclusive.
  • Neonatal Symptoms: Similar to SSRIs, there's a potential for transient neonatal symptoms (e.g., jitteriness, irritability), though generally less severe than with SSRIs.
•  

Sample Answer

        This response will focus on pregnant women and Major Depressive Disorder (MDD) as the chosen population and disorder. Treating MDD during pregnancy is a complex clinical challenge, balancing the risks of medication exposure to the fetus against the risks of untreated maternal depression for both mother and child.  

Recommendations for Treating Major Depressive Disorder in Pregnant Women

   

1. FDA-Approved Drug: Sertraline (Zoloft)

 

• Recommendation: Sertraline (a Selective Serotonin Reuptake Inhibitor - SSRI) is often considered a first-line pharmacotherapy for MDD during pregnancy when medication is indicated. It is not specifically "FDA-approved for use in pregnancy" in the sense of a dedicated indication, but rather, like most antidepressants, it falls under a general approval for MDD, and its use in pregnancy is based on extensive research into its safety profile. Among SSRIs, sertraline consistently has one of the most favorable safety profiles in pregnancy.